鉴定糖尿病性黄斑水肿及其治疗反应的遗传风险因素。
Identifying Genetic Risk Factors for Diabetic Macular Edema and the Response to Treatment.
机构信息
Menzies Institute for Medical Research, University of Tasmania, Hobart, TAS, Australia.
School of Medicine, University of Tasmania, Hobart, TAS, Australia.
出版信息
J Diabetes Res. 2020 Nov 12;2020:5016916. doi: 10.1155/2020/5016916. eCollection 2020.
Abstract
Diabetic retinopathy (DR) is the most common microvascular complication of diabetes mellitus (DM). DR is complex and the term encompasses several clinical subtypes of diabetic eye disease, including diabetic macular edema (DME), the most frequent cause of central vision loss in DR patients. Both genetic and environmental factors contribute to the pathophysiology of DR and its subtypes. While numerous studies have identified several susceptibility genes for DR, few have investigated the impact of genetics on DME susceptibility. This review will focus on the current literature surrounding genetic risk factors associated with DME. We will also highlight the small number of studies investigating the genetics of response to antivascular endothelial growth factor (anti-VEGF) injection, which is used to treat DME.
摘要
糖尿病性视网膜病变（DR）是糖尿病（DM）最常见的微血管并发症。DR 较为复杂，涵盖了几种糖尿病眼病的临床亚型，包括糖尿病黄斑水肿（DME），这是 DR 患者中心视力丧失的最常见原因。遗传和环境因素均促成了 DR 及其亚型的病理生理学变化。虽然许多研究已经确定了几个与 DR 相关的易感基因，但很少有研究调查遗传因素对 DME 易感性的影响。这篇综述将重点关注与 DME 相关的遗传危险因素的现有文献。我们还将重点介绍少数研究抗血管内皮生长因子（anti-VEGF）注射反应遗传学的研究，anti-VEGF 注射用于治疗 DME。
相似文献
1
Identifying Genetic Risk Factors for Diabetic Macular Edema and the Response to Treatment.鉴定糖尿病性黄斑水肿及其治疗反应的遗传风险因素。
J Diabetes Res. 2020 Nov 12;2020:5016916. doi: 10.1155/2020/5016916. eCollection 2020.
2
Persistent Macular Thickening Following Intravitreous Aflibercept, Bevacizumab, or Ranibizumab for Central-Involved Diabetic Macular Edema With Vision Impairment: A Secondary Analysis of a Randomized Clinical Trial.玻璃体内注射阿柏西普、贝伐单抗或雷珠单抗治疗伴有视力损害的累及中心的糖尿病性黄斑水肿后持续性黄斑增厚：一项随机临床试验的二次分析。
JAMA Ophthalmol. 2018 Mar 1;136(3):257-269. doi: 10.1001/jamaophthalmol.2017.6565.
3
Treatment strategies for refractory diabetic macular edema: switching anti-VEGF treatments, adopting corticosteroid-based treatments, and combination therapy.难治性糖尿病性黄斑水肿的治疗策略：更换抗血管内皮生长因子（anti-VEGF）治疗、采用基于皮质类固醇的治疗以及联合治疗。
Expert Opin Biol Ther. 2016;16(3):365-74. doi: 10.1517/14712598.2016.1131265. Epub 2016 Jan 12.
4
Comparison of Aflibercept, Bevacizumab, and Ranibizumab for Treatment of Diabetic Macular Edema: Extrapolation of Data to Clinical Practice.阿柏西普、贝伐单抗和雷珠单抗治疗糖尿病性黄斑水肿的比较：数据外推至临床实践
JAMA Ophthalmol. 2016 Jan;134(1):95-9. doi: 10.1001/jamaophthalmol.2015.4110.
5
Anti-VEGF Molecules for the Management of Diabetic Macular Edema.用于治疗糖尿病性黄斑水肿的抗血管内皮生长因子分子
Curr Pharm Des. 2015;21(32):4731-7. doi: 10.2174/1381612821666150909095756.
6
Recent clinically relevant highlights from the Diabetic Retinopathy Clinical Research Network.糖尿病视网膜病变临床研究网络近期的临床相关要点。
Curr Opin Ophthalmol. 2018 May;29(3):199-205. doi: 10.1097/ICU.0000000000000472.
7
Short-Term Outcomes of Aflibercept Therapy for Diabetic Macular Edema in Patients With Incomplete Response to Ranibizumab and/or Bevacizumab.阿柏西普治疗对雷珠单抗和/或贝伐单抗反应不完全的糖尿病性黄斑水肿患者的短期疗效
Ophthalmic Surg Lasers Imaging Retina. 2015 Oct;46(9):950-4. doi: 10.3928/23258160-20151008-08.
8
The Short-term Effect of a Single Lapse in Anti-Vascular Endothelial Growth Factor Treatment for Diabetic Macular Edema Within Routine Clinical Practice.在常规临床实践中单次抗血管内皮生长因子治疗糖尿病黄斑水肿的短期效果。
Am J Ophthalmol. 2020 Nov;219:215-221. doi: 10.1016/j.ajo.2020.06.040. Epub 2020 Jul 5.
9
Five-Year Outcomes after Initial Aflibercept, Bevacizumab, or Ranibizumab Treatment for Diabetic Macular Edema (Protocol T Extension Study).初始阿柏西普、贝伐单抗或雷珠单抗治疗糖尿病性黄斑水肿的 5 年结果（协议 T 扩展研究）。
Ophthalmology. 2020 Sep;127(9):1201-1210. doi: 10.1016/j.ophtha.2020.03.021. Epub 2020 Mar 29.
10
Diabetic macular edema.糖尿病性黄斑水肿。
Ophthalmologica. 2012;227 Suppl 1:21-9. doi: 10.1159/000337156. Epub 2012 Apr 24.
引用本文的文献
1
Genome-Wide Association Study to Identify Genetic Variants Associated With Diabetic Maculopathy.全基因组关联研究以鉴定与糖尿病性黄斑病变相关的基因变异
Invest Ophthalmol Vis Sci. 2025 Mar 3;66(3):55. doi: 10.1167/iovs.66.3.55.
2
Oxidative Stress Mediates Epigenetic Modifications and the Expression of miRNAs and Genes Related to Apoptosis in Diabetic Retinopathy Patients.氧化应激介导糖尿病视网膜病变患者的表观遗传修饰以及与细胞凋亡相关的微小RNA和基因的表达。
J Clin Med. 2023 Dec 22;13(1):74. doi: 10.3390/jcm13010074.
3
Anatomical and Functional Effects of an Oral Supplementation of Bromelain and Curcugreen in Patients with Focal Diabetic Macular Edema.口服菠萝蛋白酶和姜黄提取物对糖尿病性黄斑水肿患者的解剖学和功能影响
J Clin Med. 2023 Nov 26;12(23):7318. doi: 10.3390/jcm12237318.
4
AAV-Based Strategies for Treatment of Retinal and Choroidal Vascular Diseases: Advances in Age-Related Macular Degeneration and Diabetic Retinopathy Therapies.基于 AAV 的视网膜和脉络膜血管疾病治疗策略：年龄相关性黄斑变性和糖尿病性视网膜病变治疗的新进展。
BioDrugs. 2024 Jan;38(1):73-93. doi: 10.1007/s40259-023-00629-y. Epub 2023 Oct 25.
5
Genome-wide association study of the response of patients with diabetic macular edema to intravitreal Anti-VEGF injection.抗血管内皮生长因子药物玻璃体腔注射治疗糖尿病黄斑水肿患者反应的全基因组关联研究。
Sci Rep. 2022 Dec 29;12(1):22527. doi: 10.1038/s41598-022-26048-7.
6
Association of polymorphisms in the erythropoietin gene with diabetic retinopathy: a case-control study and systematic review with meta-analysis.促红细胞生成素基因多态性与糖尿病视网膜病变的相关性：病例对照研究和系统评价Meta 分析。
BMC Ophthalmol. 2022 Jun 4;22(1):250. doi: 10.1186/s12886-022-02467-y.
7
Comparing vision and macular thickness in neovascular age-related macular degeneration, diabetic macular oedema and retinal vein occlusion patients treated with intravitreal antivascular endothelial growth factor injections in clinical practice.在临床实践中，比较接受玻璃体内抗血管内皮生长因子注射治疗的新生血管性年龄相关性黄斑变性、糖尿病性黄斑水肿和视网膜静脉阻塞患者的视力和黄斑厚度。
BMJ Open Ophthalmol. 2021 May 3;6(1):e000749. doi: 10.1136/bmjophth-2021-000749. eCollection 2021.
本文引用的文献
1
Real-world management of treatment-naïve diabetic macular oedema in Japan: two-year visual outcomes with and without anti-VEGF therapy in the STREAT-DME study.日本治疗初发糖尿病性黄斑水肿的真实世界管理：STREAT-DME 研究中有无抗 VEGF 治疗的两年视觉结局。
Br J Ophthalmol. 2020 Sep;104(9):1209-1215. doi: 10.1136/bjophthalmol-2019-315199. Epub 2019 Nov 29.
2
Meta-analysis of the association between aldose reductase gene (CA)n microsatellite variants and risk of diabetic retinopathy.醛糖还原酶基因（CA）n微卫星变异与糖尿病视网膜病变风险关联的Meta分析。
Exp Ther Med. 2019 Dec;18(6):4499-4509. doi: 10.3892/etm.2019.8086. Epub 2019 Oct 8.
3
IDF Diabetes Atlas: A review of studies utilising retinal photography on the global prevalence of diabetes related retinopathy between 2015 and 2018.国际糖尿病联盟糖尿病地图集：对 2015 年至 2018 年期间利用视网膜摄影评估全球糖尿病相关视网膜病变患病率的研究的综述。
Diabetes Res Clin Pract. 2019 Nov;157:107840. doi: 10.1016/j.diabres.2019.107840. Epub 2019 Nov 14.
4
MicroRNA-Related Genetic Variants Are Associated With Diabetic Retinopathy in Type 1 Diabetes Mellitus.微小 RNA 相关遗传变异与 1 型糖尿病患者的糖尿病视网膜病变有关。
Invest Ophthalmol Vis Sci. 2019 Sep 3;60(12):3937-3942. doi: 10.1167/iovs.18-25570.
5
Erythropoietin protects outer blood-retinal barrier in experimental diabetic retinopathy by up-regulating ZO-1 and occludin.促红细胞生成素通过上调 ZO-1 和闭合蛋白来保护实验性糖尿病视网膜病变中外血视网膜屏障。
Clin Exp Ophthalmol. 2019 Dec;47(9):1182-1197. doi: 10.1111/ceo.13619. Epub 2019 Sep 15.
6
Deciphering the role of circulating lncRNAs: RNCR2, NEAT2, CDKN2B-AS1, and PVT1 and the possible prediction of anti-VEGF treatment outcomes in diabetic retinopathy patients.解读循环长链非编码RNA的作用：RNCR2、NEAT2、CDKN2B-AS1和PVT1以及糖尿病视网膜病变患者抗血管内皮生长因子治疗结果的可能预测
Graefes Arch Clin Exp Ophthalmol. 2019 Sep;257(9):1897-1913. doi: 10.1007/s00417-019-04409-9. Epub 2019 Jul 20.
7
MicroRNAs as biomarkers of diabetic retinopathy and disease progression.微小RNA作为糖尿病视网膜病变及疾病进展的生物标志物
Neural Regen Res. 2019 Nov;14(11):1858-1869. doi: 10.4103/1673-5374.259602.
8
A genome-wide association study implicates that the gene is associated with diabetic maculopathy with decreased visual acuity.一项全基因组关联研究表明，该基因与视力下降的糖尿病性黄斑病变有关。
Ophthalmic Genet. 2019 Jun;40(3):252-258. doi: 10.1080/13816810.2019.1633549. Epub 2019 Jul 2.
9
Association Between Change in Visual Acuity and Change in Central Subfield Thickness During Treatment of Diabetic Macular Edema in Participants Randomized to Aflibercept, Bevacizumab, or Ranibizumab: A Post Hoc Analysis of the Protocol T Randomized Clinical Trial.随机接受阿柏西普、贝伐单抗或雷珠单抗治疗的糖尿病性黄斑水肿患者在治疗期间视力变化与中心子野厚度变化之间的关联：Protocol T随机临床试验的事后分析
JAMA Ophthalmol. 2019 Sep 1;137(9):977-985. doi: 10.1001/jamaophthalmol.2019.1963.
10
MicroRNA-145 Regulates Pathological Retinal Angiogenesis by Suppression of TMOD3.微小RNA-145通过抑制TMOD3调节病理性视网膜血管生成。
Mol Ther Nucleic Acids. 2019 Jun 7;16:335-347. doi: 10.1016/j.omtn.2019.03.001. Epub 2019 Mar 21.
Zotero 插件